Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
VTGN 
VistaGen Therapeutics Inc (VTGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: VTGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0.97
1 Year Target Price $0.97
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.98% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.80M USD | Price to earnings Ratio - | 1Y Target Price 0.97 |
Price to earnings Ratio - | 1Y Target Price 0.97 | ||
Volume (30-day avg) 4 | Beta 0.3 | 52 Weeks Range 0.63 - 5.14 | Updated Date 01/9/2026 |
52 Weeks Range 0.63 - 5.14 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7772.48% |
Management Effectiveness
Return on Assets (TTM) -44.62% | Return on Equity (TTM) -78.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -47513102 | Price to Sales(TTM) 38.55 |
Enterprise Value -47513102 | Price to Sales(TTM) 38.55 | ||
Enterprise Value to Revenue 76.82 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 39495451 | Shares Floating 29185558 |
Shares Outstanding 39495451 | Shares Floating 29185558 | ||
Percent Insiders 0.27 | Percent Institutions 57.87 |
Upturn AI SWOT
VistaGen Therapeutics Inc
Company Overview
History and Background
VistaGen Therapeutics Inc. was founded in 2005. It is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. A significant milestone includes advancing its lead drug candidate into later-stage clinical trials.
Core Business Areas
- CNS Therapeutics Development: VistaGen is dedicated to discovering, developing, and commercializing innovative small molecule drugs for the treatment of neurological and psychiatric conditions. Their primary focus is on unmet medical needs within these therapeutic areas.
Leadership and Structure
Information on the current leadership team and detailed organizational structure is best obtained from the company's official investor relations website or SEC filings, as this can change.
Top Products and Market Share
Key Offerings
- AV-101: AV-101 is VistaGen's lead drug candidate, a novel oral N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neurological and psychiatric disorders, including epilepsy, depression, and neuropathic pain. Competitors in this space include companies developing other NMDA receptor modulators or drugs targeting similar pathways. Specific market share data for AV-101 is not yet available as it is still in clinical development.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the CNS disorder segment, is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. There is a substantial unmet need for effective treatments for many neurological and psychiatric conditions, driving innovation and investment.
Positioning
VistaGen Therapeutics is positioned as a clinical-stage biopharmaceutical company aiming to address unmet needs in the CNS therapeutic area. Its competitive advantage lies in its differentiated approach to targeting specific receptor pathways like the NMDA receptor, potentially offering novel mechanisms of action compared to existing therapies.
Total Addressable Market (TAM)
The total addressable market for CNS disorders is vast, encompassing conditions like depression, epilepsy, anxiety, and neuropathic pain, with global market values in the hundreds of billions of dollars. VistaGen Therapeutics is positioned to address a significant portion of this TAM if its lead candidate and pipeline products achieve regulatory approval and market adoption.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (AV-101) with a differentiated mechanism of action targeting NMDA receptors.
- Focus on significant unmet medical needs in CNS disorders.
- Potential for broad therapeutic applications across multiple indications.
Weaknesses
- Clinical-stage company with no approved products, implying high development risk.
- Reliance on successful outcomes from ongoing clinical trials.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Growing market demand for effective CNS disorder treatments.
- Potential for strategic partnerships or acquisitions by larger pharmaceutical companies.
- Advancement of AV-101 through clinical trial phases towards regulatory approval.
Threats
- Failure to demonstrate efficacy or safety in clinical trials.
- Regulatory hurdles and delays in drug approval processes.
- Competition from existing therapies and new entrants in the CNS market.
- Funding challenges in early-stage biopharmaceutical development.
Competitors and Market Share
Key Competitors
- Alkermes plc (ALKS)
- Karuna Therapeutics, Inc. (KRTX) (Acquired by BMS)
- Axsome Therapeutics, Inc. (AXSM)
Competitive Landscape
VistaGen's competitive advantage lies in its specific focus on the NMDA receptor pathway with AV-101, potentially offering a novel approach compared to many existing treatments for CNS disorders. However, it faces significant competition from established pharmaceutical companies with broader portfolios and greater resources, as well as other biotechs developing innovative CNS therapies.
Growth Trajectory and Initiatives
Historical Growth: Historically, VistaGen's growth has been characterized by progress in its drug development pipeline, moving from preclinical research to various phases of clinical trials. This growth is measured by scientific advancements and clinical progress rather than traditional revenue growth.
Future Projections: Future projections are speculative and heavily dependent on the successful completion of clinical trials and subsequent regulatory approvals for AV-101 and any other pipeline candidates. Analyst projections would focus on potential peak sales of approved drugs and the valuation of the company based on its development stage.
Recent Initiatives: Recent initiatives likely include the advancement of AV-101 into later-stage clinical trials, securing necessary funding for ongoing development, and potentially expanding its pipeline or forming strategic collaborations.
Summary
VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel CNS therapies, with its lead candidate AV-101 targeting unmet medical needs. The company's strength lies in its differentiated approach and the significant market potential for effective CNS treatments. However, it faces substantial risks inherent in drug development, including clinical trial failures and regulatory hurdles, and relies heavily on continued funding to advance its pipeline.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the U.S. Securities and Exchange Commission (SEC)
- Financial news and data providers
- Industry research reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Investment decisions should be made after consulting with a qualified financial advisor and conducting thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About VistaGen Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2016-05-06 | President, CEO & Director Mr. Shawn K. Singh J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.vistagen.com |
Full time employees 59 | Website https://www.vistagen.com | ||
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.